A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution - Trial NCT05501860
Access comprehensive clinical trial information for NCT05501860 through Pure Global AI's free database. This Phase 3 trial is sponsored by American Genomics, LLC and is currently Not yet recruiting. The study focuses on Anesthesia, Local. Target enrollment is 240 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
American Genomics, LLC
Timeline & Enrollment
Phase 3
Jul 30, 2022
Dec 07, 2022
Primary Outcome
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Summary
A Phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects.
 It is designed to evaluate the ocular safety of a single topical ocular administration of
 AG-920 sterile topical ophthalmic solution compared to placebo..
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05501860
Non-Device Trial